Valued at a market cap of $68.8 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, and commercializes antibody-based medicines for serious diseases. Headquartered in Tarrytown, New York, the company is known for leveraging its proprietary genetic research and antibody technologies to develop innovative therapies.
REGN is scheduled to announce its fiscal Q2 earnings for 2026 before the market opens on Thursday, July 30. Ahead of the release, **** ysts expect this healthcare company to report a profit of $8 per share, down 25.4% from $10.72 per share in the year-ago quarter. The company has topped Wall Street's bottom-line estimates in each of the last four quarters.
Dear **** eX Stock Fans, Mark Your Calendars for July 23
Walmart Stock's Extended Downturn Could Trigger a Possible Comeback
The Biggest Risk to **** eX Stock Comes After Earnings. Here Are The Numbers You Should Keep An Eye On.
#regn #SpaceX
REGN is scheduled to announce its fiscal Q2 earnings for 2026 before the market opens on Thursday, July 30. Ahead of the release, **** ysts expect this healthcare company to report a profit of $8 per share, down 25.4% from $10.72 per share in the year-ago quarter. The company has topped Wall Street's bottom-line estimates in each of the last four quarters.
Dear **** eX Stock Fans, Mark Your Calendars for July 23
Walmart Stock's Extended Downturn Could Trigger a Possible Comeback
The Biggest Risk to **** eX Stock Comes After Earnings. Here Are The Numbers You Should Keep An Eye On.
#regn #SpaceX
3 months ago
